Australia; International; ACT
Semaglutide, the diabetes drug that has now become best known for its weight loss properties, can help reduce heart failure–related symptoms and physical limitations in obese people with diabetes, as well as increasing their weight loss, according to Australian and international research. The researchers looked at around 600 diabetics with heart failure who were also obese to receive either once-weekly semaglutide (2.4 mg) or placebo for a year. After a year they found fewer symptoms and physical limitations in the semaglutide group and this group also reduced their bogy weight by 9.8% compared to 3.4% with placebo.
From:
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
